Source comparison
Tesamorelin Legal 2026 Status: Research-Grade vs Clinical-Grade
FDA-Approved Egrifta Fully FDA-approved for HIV lipodystrophy Clinical treatment in diagnosed patients Yes. Valid prescription mandatory Retail pharmacies, specialty HIV pharmacies Gold standard for traceability and batch consistency. Highest cost. Compounded
This comparison does not assign a generated winner or score.
- FDA-Approved Egrifta
- Fully FDA-approved for HIV lipodystrophy
- Clinical treatment in diagnosed patients
- Yes. Valid prescription mandatory
- Retail pharmacies, specialty HIV pharmacies
- Gold standard for traceability and batch consistency. Highest cost.
- Compounded Tesamorelin (503B)
- Legal under federal compounding exemptions
- Off-label clinical use, personalized dosing
- 503B outsourcing facilities, compounding pharmacies
- Same active molecule as Egrifta, lower cost. No finished-product FDA approval.
- Research-Grade Tesamorelin
- Legal for institutional research only
- Non-human in vitro or in vivo research
- No. Institutional purchase only
- Licensed peptide suppliers to labs and universities
- Not for human use. Sold to institutions, not individuals. Purity varies.
- Gray-Market Tesamorelin
- Illegal to sell without prescription
- Marketed 'for research' to individuals
- Claimed 'not for human use'. Actual prescriptions absent
- Unregulated online vendors, overseas suppliers
- High contamination risk. No legal recourse. Violates FDA regulations.
- The table above clarifies the tesamorelin legal 2026 status across access pathways. The key distinction: research-grade tesamorelin sold 'for research purposes only' to individual consumers is a regulatory workaround, not a legal exemption. The FDA's position is clear. Peptides marketed for human use require prescriptions, regardless of disclaimers.